Literature DB >> 8770389

Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.

A J Bridges1, D R Cody, H Zhou, A McMichael, D W Fry.   

Abstract

4-Benzylaminoquinazolines can be potent reversible inhibitors of the EGFR tyrosine kinase at the ATP binding site. Examination of benzylic methylation reveals that an (R)-methyl group is four- to six-fold activating, with an optimal Ki of 630 pM for compound 11. In sharp contrast, (S)-methylation causes a > 30 to 500-fold loss of inhibitory activity, showing that the ATP-binding site of the receptor has very low tolerance for even moderate out-of-plane bulk in certain directions. It is suggested that the best of these inhibitors can induce a conformation of the kinase not available to poorer inhibitors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8770389     DOI: 10.1016/0968-0896(95)00149-2

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.

Authors:  Masahiko Hirata; Yasukazu Kanai; Sadahiro Naka; Mitsuyoshi Yoshimoto; Shinya Kagawa; Keiji Matsumuro; Hideyuki Katsuma; Hiroshi Yamaguchi; Yasuhiro Magata; Yoshiro Ohmomo
Journal:  Ann Nucl Med       Date:  2013-03-15       Impact factor: 2.668

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.